Series: Landmark Trials in Endocrinology & Metabolism | Study #12
Category: Obesity & Weight Management | Design: Multicentre, double-blind, placebo-controlled RCT | n: 2,539 | Follow-up: 72 weeks
📋 Summary
Authors: Jastreboff AM et al., for the SURMOUNT-1 Investigators
Journal: N Engl J Med 2022;387:205–216 | DOI: 10.1056/NEJMoa2206038
SURMOUNT-1 evaluated tirzepatide — a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — in 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomly assigned to tirzepatide 5 mg, 10 mg, or 15 mg once weekly, or placebo, for 72 weeks, all with lifestyle counselling. The co-primary endpoints were the percentage change in body weight from baseline and the proportion of participants achieving a weight reduction of 5% or more. At week 72, mean weight reductions were 15.0% with tirzepatide 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, compared with 3.1% with placebo (p<0.001 for all dose comparisons). Proportions achieving 5% or more weight loss were 85%, 89%, and 91% respectively, versus 35% with placebo. Reductions of 20% or more in body weight were achieved by 30%, 50%, and 57% of participants on tirzepatide 5, 10, and 15 mg respectively, compared with 3% on placebo — a weight loss magnitude that overlaps with outcomes historically achieved only with bariatric surgery. All three tirzepatide doses produced significant improvements in cardiometabolic parameters including waist circumference, blood pressure, fasting glucose, HbA1c, lipids, and markers of insulin resistance. Gastrointestinal adverse events, primarily nausea and diarrhoea, were the most common side effects and were predominantly mild to moderate in severity.
📊 Key Findings
| Outcome | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Mean % weight change | −15.0% | −19.5% | −20.9% | −3.1% |
| ≥5% weight loss | 85% | 89% | 91% | 35% |
| ≥10% weight loss | 69% | 79% | 83% | 17% |
| ≥15% weight loss | 51% | 67% | 73% | 8% |
| ≥20% weight loss | 30% | 50% | 57% | 3% |
| All comparisons vs placebo: p<0.001 | ||||
💬 Expert Commentary
SURMOUNT-1 established tirzepatide as the most potent pharmacological agent for weight loss yet evaluated in a randomised controlled trial. The mean weight reduction of 20.9% at the highest dose, with 57% of participants losing 20% or more, substantially exceeded the results from STEP 1 (semaglutide 2.4 mg, −14.9%) and for the first time produced weight loss outcomes in a drug trial that are comparable in magnitude to the results reported for laparoscopic sleeve gastrectomy in observational and small randomised studies. This comparison has generated considerable discussion about whether pharmacological and surgical approaches to obesity are now more comparable in efficacy than previously assumed, and whether the long-term durability of drug-induced weight loss can match that of surgical approaches — a question not yet resolved by the available data.
The mechanism of the additional weight loss with tirzepatide compared with GLP-1 receptor agonism alone is attributed to the additive GIP receptor signalling. GIP receptor activation in adipose tissue and the central nervous system appears to enhance the appetite-suppressive and thermogenic effects of GLP-1 receptor agonism, and the pharmacology of the combined receptor agonist differs from simple additivity in ways that are not fully characterised. What is clear from SURMOUNT-1 is that dual agonism produces a weight loss signal substantially larger than what was achieved with semaglutide alone, even at the higher 2.4 mg dose. The cardiometabolic secondary endpoints, including reductions in HbA1c of over 2% in some participants, blood pressure reductions of 7–8 mmHg systolic, and favourable lipid changes, suggest that tirzepatide produces metabolic improvements beyond what can be explained by weight loss alone. Whether this metabolic benefit translates into hard cardiovascular outcomes in non-diabetic populations is under evaluation in the SURMOUNT-MMO trial.
Limitations: The 72-week duration does not address long-term weight maintenance after treatment cessation; the SURMOUNT-4 discontinuation trial reported significant weight regain. Cardiovascular hard endpoints were not assessed. The majority of enrolled participants were women (67%), which may affect generalisability. The study was industry-sponsored by Eli Lilly.
🔑 BOTTOM LINE
SURMOUNT-1 demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent mean weight reductions of 15.0–20.9% in adults with obesity without diabetes, with 57% of participants on the highest dose losing 20% or more of body weight, setting a new pharmacological benchmark that overlaps with surgical weight loss outcomes for the first time.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
Next in the series: Study #13 SELECT: Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes
